ドライアイ治療の世界市場：洞察、競合情勢、市場予測：2032年

ドライアイ治療の市場規模は、2024年に61億8,821万米ドルとなりました。同市場は、2025年から2032年までの予測期間中にCAGR 5.29％で成長し、2032年には92億8,885万米ドルに達すると予測されています。ドライアイ治療に対するニーズの高まりは、世界の有病率の上昇が主な要因です。主な要因としては、高齢者人口の増加が挙げられ、高齢者は加齢に伴う涙の分泌量や眼の健康状態の変化により、ドライアイ症状を発症しやすくなっています。さらに、大手市場開拓企業による製品開発の増加や頻繁な新製品の発売が、市場の勢いをさらに後押ししています。こうした動向は持続的な成長に向けた良好な環境を生み出しており、ドライアイ治療市場は2025年から2032年にかけて堅調かつ着実に拡大するものと思われます。

ドライアイ治療市場力学：

The Ocular Surface（2024）に掲載された最近の研究によると、2024年には世界で3億4,400万人以上がドライアイ（DED）に罹患し、疾病負担が著しく増大していることが明らかになっています。このような有病率の上昇は、効果的な治療オプションに対する世界の需要に拍車をかけています。DED治療薬は、目に潤いを与え、炎症を抑えることで症状を緩和する重要な役割を担っています。

DelveInsight Analysis（2025）のデータによると、2023年だけで、日本では男性230万人以上、女性830万人以上がDEDと診断されました。英国でも同様に負担が大きく、軽症が約280万人、中等症が約130万人、重症が約200万人と報告されています。さらに、Nature誌に発表された2023年の研究では、中国では約4億人がDEDに罹患していると推定され、これはおよそ5人に1人から2人の割合に相当します。

これらの憂慮すべき統計は、この疾患の広範な性質を浮き彫りにし、多様な地域に的を絞った治療介入が緊急に必要であることを強調しています。DEDの罹患率の上昇は、長時間のスクリーン使用、環境的ストレス要因、高齢化、ライフスタイルの変化など、いくつかの集約的な要因によって引き起こされています。これらの要素は総体的に世界の患者数を拡大し、従来の治療法と先進的な治療ソリューションの両方に対する需要を煽っています。

市場成長の特に有力な促進要因は、世界人口の高齢化です。涙の分泌量は加齢とともに減少する傾向にあり、その結果、眼表面の潤滑が不十分となり、DEDに罹患しやすくなります。国連のデータ（2023年）によると、65歳以上の人口は2021年の7億6,100万人から2050年には16億人に倍増すると予測されています。80歳以上の人口はさらに急増すると予想されています。

こうした需要の高まりを受けて、市場の主要企業は革新的な治療法の開発を加速させています。例えば、Alconは2025年5月、米国食品医薬品局（FDA）がDEDの徴候・症状の治療薬としてTRYPTYR（R）（アコルトレモン点眼液）0.003％（旧名AR-15512）を承認したと発表しました。TRYPTYRはファーストインクラスのTRPM8受容体作動薬（神経調節薬）で、角膜知覚神経を刺激し、自然な涙の分泌を速やかに促進します。

同様に、2025年5月、Aldeyra Therapeutics, Inc. は、同社の治験薬候補である0.25%プロプレキサラップ点眼液が、DED治療を対象とした第3相無作為化二重マスク、ビヒクル対照ドライアイチャンバー試験において主要評価項目を達成したと発表しました。

患者数の増加、認知度の向上、技術の進歩が相まって、DED治療市場は2025年以降に大きく成長するものと思われます。

しかし、ドライアイ治療に伴う合併症や安全性への懸念、製品承認に必要な厳しい規制要件などが、ドライアイ治療市場の成長を制限する可能性のある主要な制約となっています。

ドライアイ治療市場セグメント分析：

ドライアイ治療市場：製品タイプ（人工涙液、デバイス、医薬品、その他）、流通チャネル（病院・小売薬局、オンライン薬局）、地域（北米、欧州、アジア太平洋地域、その他アジア地域）別

ドライアイ治療市場の製品タイプ別では、人工涙液カテゴリーが2024年に最大の市場シェアを占めると推定されます。このカテゴリの成長は、主にDEDの世界の有病率の上昇と、人工涙液がこの症状を管理する上で提供する幅広い治療上の利点によってもたらされます。

人工涙液は、眼球の自然な涙液膜を補足または代替することで、DED管理において中心的な役割を果たします。人工涙液は眼表面の水分を維持し、乾燥感、刺激感、灼熱感、チクチク感などの一般的な症状を即座に緩和します。また、これらの点眼薬は、患者がしばしば報告するギトギト感や砂のような感覚を軽減し、長時間の画面使用、読書、低湿度環境での過ごし方など、日常生活をより快適で扱いやすいものにします。

症状の緩和だけでなく、人工涙液は角膜と結膜に保護バリアを形成し、まばたきやまぶたの動きによる機械的摩擦を最小限に抑えるのに役立ちます。これは快適さを向上させるだけでなく、特に慢性的なドライアイや重度のドライアイの場合、眼表面のさらなる損傷から保護します。もう1つの重要な利点は、DEDの進行に重大な影響を与える眼表面の炎症を抑えることです。人工涙液の中には、炎症を鎮め、治癒をサポートする成分を含むものもあり、症状の緩和以上の効果をもたらします。

さらに、人工涙液は涙液膜の3つの重要な層（脂質、水、ムチン）を修復し、安定化させます。このデリケートな構造を強化することで、人工涙液は眼表面の潤滑性を高め、涙の蒸発を抑えます。市場成長は、研究開発投資の増加と製品革新によっても後押しされています。例えば、2022年1月、NovaBay Pharmaceuticalsは、ドライアイの症状に悩む人々に迅速かつ持続的な救済を提供するために特別に処方されたAvenova（R）Lubricating Eye Dropsを発売しました。このような革新は、このセグメントのダイナミックな可能性と、患者人口の多様なニーズを満たすための継続的な進化を浮き彫りにしています。

したがって、上記のような要因がこの市場セグメントを押し上げ、ひいては世界中のドライアイ治療市場全体を拡大すると考えられます。

北米がドライアイ治療市場全体を支配すると予測される：

北米は、いくつかの重要な要因によって、2024年にはドライアイ治療市場で最大のシェアを占めると予測されています。この地域的優位性は、主にドライアイとそれに関連する危険因子の有病率の上昇、高齢化人口の増加、主要市場参入企業による製品開拓と規制当局による承認の進行に起因しています。これらの要因を総合すると、北米は世界のドライアイ治療市場をリードする市場となっています。

米国国立衛生研究所（National Institutes of Health）のデータ（2025年）によると、米国では2024年に約1,640万人がドライアイ（DED）と共に生活しています。この動向をさらに裏付けるように、DelveInsight Analysis（2025）は、米国におけるDEDの総診断有病率は2023年に約2,250万例に達したと報告しています。同様に、シェーグレン・カナダ（2022年）のデータによると、カナダ人口の30％以上がドライアイに罹患しており、北米全域にこの疾患が広がっていることを反映しています。人口動態の高齢化、スクリーン使用時間の増加、環境的ストレス要因に起因するDED患者数の増加が、人工涙液、医療機器、先進治療薬など幅広い治療選択肢に対する需要を促進しています。

人口の増加も市場拡大に重要な役割を果たしています。人口問題研究所（2024年）によると、米国の65歳以上の人口は2022年の5,800万人から2050年には8,200万人に47%増加すると予測されています。この人口動態の変化により、総人口に占める高齢者の割合は17%から23%に上昇し、加齢がこの疾患の主要な危険因子であることから、DED治療に対する需要が大幅に高まることになります。

市場の成長は、ドライアイ治療分野における継続的な技術革新を反映した、最近の相次ぐ製品の承認と上市によってさらに後押しされています。2023年6月、Novaliq GmbHは、米国食品医薬品局（FDA）がドライアイの徴候および症状の治療薬としてVEVYE（TM）（シクロスポリン点眼液）0.1％を承認したと発表しました。さらに最近では、2025年2月、アイケアの世界リーダーであるAlconが、米国でSYSTANE（R）PRO Preservative-Free（PF）を発売しました。この市販の目薬は、独自のトリプルアクション、防腐剤フリーの処方を特徴とし、現在、SYSTANEシリーズの中で最も長持ちする製品であり、灼熱感、乾燥感、炎症を長時間緩和します。

疾患負担の増加、高齢者人口の拡大、革新的な製品の継続的な導入などを総合すると、2025年から2032年までの予測期間を通じて、北米ドライアイ治療市場は力強く持続的な成長を遂げると予想されます。

ドライアイ治療市場の主要参入企業

ドライアイ治療市場に参入している主な市場参入企業には、Alcon Inc.、Johnson &Johnson Services, Inc.、Sight Sciences、AbbVie Inc.、Lumenis Be Ltd.、Bausch Health Companies Inc.、Sun Pharmaceutical Industries Ltd.、Aldeyra Therapeutics, Inc、Viatris Inc.、Tarsus Pharmaceuticals, Inc.、MiBo Medical Group、Horus Pharma、OASIS Medical, Inc.、VISUfarma、Santen Pharmaceutical Co., Ltd.、Sentiss、Otsuka Pharmaceutical Co., Ltd.、Novaliq GmbH、AFT Pharmaceuticals、NovaBay Pharmaceuticals, Inc.などがあります。

ドライアイ治療市場における最近の開発活動：

• 2025年5月、Grifolsは、ドライアイ治療薬として開発中の免疫グロブリン（IG）点眼薬GRF312点眼液の第2相臨床試験開始に向けた治験許可申請を米国食品医薬品局（FDA）から受理されました。
• 2024年5月、Nordic Pharma, Inc.はドライアイの新規治療薬LACRIFILL Canalicular Gelを米国で発売しました。ラクリフィルは架橋型ヒアルロン酸誘導体で、涙小管系を閉塞することで涙の排出を一時的に遮断し、眼表面の水分保持を助けることがFDAの認可を受けています。
• 2024年1月、Alconは、ドライアイ治療薬AR-15512の有効性と安全性を評価したCOMET-2とCOMET-3の2つの重要な臨床第3相試験から良好な結果が得られたと発表しました。
• 2023年9月、Bausch + Lomb Corporationはドライアイ治療薬MIEBO（パーフルオロヘキシロオクタン点眼液）を米国で発売すると発表しました。MIEBOは、ドライアイの根本的な原因である涙液の蒸発を抑制することを目的として承認された、最初で唯一の処方箋点眼薬です。

ドライアイ治療薬市場調査報告書の主な内容

• 現在のドライアイ治療薬市場規模分析（2024年）と8年間（2025年～2032年）の市場予測
• 過去3年間に起こった主な製品/技術開発、合併、買収、提携、合弁事業
• ドライアイ治療市場を独占する主要企業。
• ドライアイ治療市場において競合他社が利用できる様々な機会。
• 2024年に上位を占めるセグメントと2032年におけるこれらのセグメントの業績
• 現在のドライアイ治療市場シナリオにおいて、上位の業績を上げている地域と国
• 今後のドライアイ治療市場の成長機会に企業が集中すべき地域と国

ドライアイ治療市場のよくある質問

1.ドライアイ

• ドライアイ治療とは、ドライアイ（DED）患者の症状を緩和し、涙の質と量を回復させ、眼表面の健康を改善することを目的とした、医学的、治療的、生活習慣的介入の範囲を指します。その目的は、不快感を軽減し、眼表面の損傷を防ぎ、視機能を改善することです。

2.ドライアイ治療市場

• ドライアイ治療市場は、2024年には61億8,821万米ドルとなり、2025年から2032年までの予測期間中にCAGR 5.29％で成長し、2032年には92億8,885万米ドルに達します。

3.ドライアイ治療市場の促進要因は

• ドライアイ治療に対するニーズの高まりは、世界の有病率の上昇が主な要因です。主な要因としては、高齢者人口の拡大が挙げられます。高齢者人口は、加齢に伴う涙の分泌量や眼の健康状態の変化により、ドライアイ症状を発症しやすくなっています。さらに、大手市場開拓企業別製品開発の増加や頻繁な新製品の発売が、市場の勢いをさらに後押ししています。こうした動向は持続的な成長に向けた良好な環境を生み出しており、ドライアイ治療市場は2025年から2032年にかけて堅調かつ着実に拡大するものと思われます。

4.ドライアイ治療市場で事業を展開する主要企業

• ドライアイ治療市場に参入している主な市場参入企業には、Alcon Inc.、Johnson &Johnson Services, Inc.、Sight Sciences、AbbVie Inc.、Lumenis Be Ltd.、Bausch Health Companies Inc.、Sun Pharmaceutical Industries Ltd.、Aldeyra Therapeutics, Inc、Viatris Inc.、Tarsus Pharmaceuticals, Inc.、MiBo Medical Group、Horus Pharma、OASIS Medical, Inc.、VISUfarma、Santen Pharmaceutical Co., Ltd.、Sentiss、Otsuka Pharmaceutical Co., Ltd.、Novaliq GmbH、AFT Pharmaceuticals、NovaBay Pharmaceuticals, Inc.などがあります。

5.ドライアイ治療薬市場で最もシェアが高い地域

• 北米は、いくつかの重要な要因別、2024年にはドライアイ治療市場で最大のシェアを占めると予測されています。この地域の優位性は、主にドライアイ疾患とそれに関連する危険因子の有病率の上昇、高齢化人口の増加、主要市場参入企業による進行中の製品開拓と薬事承認に起因しています。これらの要因を総合すると、北米は世界のドライアイ治療市場をリードする市場であるといえます。

目次

第1章 ドライアイ治療市場レポートのイントロダクション

第2章 ドライアイ治療市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 ドライアイ治療市場の主な要因分析

• ドライアイ治療市場促進要因
  • 世界中でドライアイの罹患率が増加
  • 高齢者人口の増加と疾病に対する意識と検出の高まり
  • 主要参入企業による製品開発および発売活動の増加
• ドライアイ治療市場抑制要因と課題
  • ドライアイ治療に伴う合併症と安全性の懸念
  • 製品承認のための厳格な規制要件
• ドライアイ治療市場の機会
  • 再生医療および生物学的療法の開発

第6章 ドライアイ治療市場におけるポーターのファイブフォース分析

第7章 ドライアイ治療市場の評価

• 製品タイプ別
  • 人工涙液
  • デバイス
  • 薬物
  • その他
• 流通チャネル別
  • 病院および薬局
  • オンライン薬局
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 ドライアイ治療市場の企業と製品プロファイル

• Alcon Inc.
• Johnson & Johnson Services, Inc.
• Sight Sciences
• AbbVie Inc.
• Lumenis Be Ltd.
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Aldeyra Therapeutics, Inc.
• Viatris Inc
• Tarsus Pharmaceuticals, Inc.
• MiBo Medical Group
• Horus Pharma
• OASIS Medical, Inc.
• VISUfarma
• Santen Pharmaceutical Co., Ltd.
• Sentiss
• Otsuka Pharmaceutical Co., Ltd.
• Novaliq GmbH
• AFT Pharmaceuticals
• NovaBay Pharmaceuticals, Inc.

第9章 KOLの見解

第10章 プロジェクトアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Dry Eye Disease Treatment Market in Global (2022-2032)
• Table 3: Dry Eye Disease Treatment Market in Global by Product Type (2022-2032)
• Table 4: Dry Eye Disease Treatment Market in Global by Distribution Channel (2022-2032)
• Table 5: Dry Eye Disease Treatment Market in Global by Geography (2022-2032)
• Table 6: Dry Eye Disease Treatment Market in North America (2022-2032)
• Table 7: Dry Eye Disease Treatment Market in the United States (2022-2032)
• Table 8: Dry Eye Disease Treatment Market in Canada (2022-2032)
• Table 9: Dry Eye Disease Treatment Market in Mexico (2022-2032)
• Table 10: Dry Eye Disease Treatment Market in Europe (2022-2032)
• Table 11: Dry Eye Disease Treatment Market in France (2022-2032)
• Table 12: Dry Eye Disease Treatment Market in Germany (2022-2032)
• Table 13: Dry Eye Disease Treatment Market in United Kingdom (2022-2032)
• Table 14: Dry Eye Disease Treatment Market in Italy (2022-2032)
• Table 15: Dry Eye Disease Treatment Market in Spain (2022-2032)
• Table 16: Dry Eye Disease Treatment Market in the Rest of Europe (2022-2032)
• Table 17: Dry Eye Disease Treatment Market in Asia-Pacific (2022-2032)
• Table 18: Dry Eye Disease Treatment Market in China (2022-2032)
• Table 19: Dry Eye Disease Treatment Market in Japan (2022-2032)
• Table 20: Dry Eye Disease Treatment Market in India (2022-2032)
• Table 21: Dry Eye Disease Treatment Market in Australia (2022-2032)
• Table 22: Dry Eye Disease Treatment Market in South Korea (2022-2032)
• Table 23: Dry Eye Disease Treatment Market in Rest of Asia-Pacific (2022-2032)
• Table 24: Dry Eye Disease Treatment Market in the Rest of the World (2022-2032)
• Table 25: Dry Eye Disease Treatment Market in the Middle East (2022-2032)
• Table 26: Dry Eye Disease Treatment Market in Africa (2022-2032)
• Table 27: Dry Eye Disease Treatment Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Dry Eye Disease Treatment Market in Global (2022-2032)
• Figure 3: Dry Eye Disease Treatment Market in Global by Product Type (2022-2032)
• Figure 4: Dry Eye Disease Treatment Market in Global by Distribution Channel (2022-2032)
• Figure 5: Dry Eye Disease Treatment Market in Global by Geography (2022-2032)
• Figure 6: Dry Eye Disease Treatment Market in North America (2022-2032)
• Figure 7: Dry Eye Disease Treatment Market in the United States (2022-2032)
• Figure 8: Dry Eye Disease Treatment Market in Canada (2022-2032)
• Figure 9: Dry Eye Disease Treatment Market in Mexico (2022-2032)
• Figure 10: Dry Eye Disease Treatment Market in Europe (2022-2032)
• Figure 11: Dry Eye Disease Treatment Market in France (2022-2032)
• Figure 12: Dry Eye Disease Treatment Market in Germany (2022-2032)
• Figure 13: Dry Eye Disease Treatment Market in United Kingdom (2022-2032)
• Figure 14: Dry Eye Disease Treatment Market in Italy (2022-2032)
• Figure 15: Dry Eye Disease Treatment Market in Spain (2022-2032)
• Figure 16: Dry Eye Disease Treatment Market in the Rest of Europe (2022-2032)
• Figure 17: Dry Eye Disease Treatment Market in Asia-Pacific (2022-2032)
• Figure 18: Dry Eye Disease Treatment Market in China (2022-2032)
• Figure 19: Dry Eye Disease Treatment Market in Japan (2022-2032)
• Figure 20: Dry Eye Disease Treatment Market in India (2022-2032)
• Figure 21: Dry Eye Disease Treatment Market in Australia (2022-2032)
• Figure 22: Dry Eye Disease Treatment Market in South Korea (2022-2032)
• Figure 23: Dry Eye Disease Treatment Market in Rest of Asia-Pacific (2022-2032)
• Figure 24: Dry Eye Disease Treatment Market in the Rest of the World (2022-2032)
• Figure 25: Dry Eye Disease Treatment Market in the Middle East (2022-2032)
• Figure 26: Dry Eye Disease Treatment Market in Africa (2022-2032)
• Figure 27: Dry Eye Disease Treatment Market in South America (2022-2032)
• Figure 28: Market Drivers
• Figure 29: Market Barriers
• Figure 30: Marker Opportunities
• Figure 31: PORTER'S Five Force Analysis

Dry Eye Disease Treatment Market by Product Type (Artificial Tears, Devices, Drugs, and, Others), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of dry eye disease globally and increasing product development and launches activities by key players.

The dry eye disease treatment market was valued at USD 6,188.21 million in 2024, growing at a CAGR of 5.29% during the forecast period from 2025 to 2032 to reach USD 9,288.85 million by 2032. The growing need for dry eye disease treatment is primarily driven by the rising global prevalence of the condition. A key contributing factor is the expanding geriatric population, which is more susceptible to developing dry eye symptoms due to age-related changes in tear production and ocular health. Additionally, increased product development and frequent new launches by leading market players are further supporting market momentum. These trends are creating a favorable environment for sustained growth, positioning the dry eye disease treatment market for robust and steady expansion from 2025 to 2032.

Dry Eye Disease Treatment Market Dynamics:

According to a recent study published in The Ocular Surface (2024), in 2024, over 344 million people worldwide were affected by Dry Eye Disease (DED), underscoring a significant and growing disease burden. This rising prevalence is fueling the global demand for effective treatment options. DED therapies play a vital role in relieving symptoms by moisturizing the eyes and reducing irritation.

Data from DelveInsight Analysis (2025) revealed that in 2023 alone, over 2.3 million males and 8.3 million females in Japan were diagnosed with DED. In the United Kingdom, the burden was similarly high, with approximately 2.8 million mild, 1.3 million moderate, and 2 million severe cases reported. Additionally, a 2023 study published in Nature estimated that around 400 million individuals in China suffered from DED, equating to roughly one to two out of every five people.

These alarming statistics highlight the widespread nature of the condition and emphasize the urgent need for targeted therapeutic interventions across diverse regions. The increasing incidence of DED is driven by several converging factors, including prolonged screen time, environmental stressors, aging populations, and lifestyle changes. These elements are collectively expanding the global patient population and fueling demand for both conventional therapies and advanced treatment solutions.

A particularly influential driver of market growth is the aging global population. Tear production tends to decline with age, resulting in insufficient lubrication of the ocular surface and increasing susceptibility to DED. According to data from the United Nations (2023), the number of individuals aged 65 years or older was projected to more than double from 761 million in 2021 to 1.6 billion by 2050. The population aged 80 and older is expected to grow even more rapidly.

In response to this rising demand, key market players are accelerating the development of innovative treatment options. For instance, in May 2025, Alcon announced that the U.S. Food and Drug Administration (FDA) had approved TRYPTYR(R) (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of DED. TRYPTYR is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to promote natural tear production rapidly.

Similarly, in May 2025, Aldeyra Therapeutics, Inc. announced that its investigational drug candidate, 0.25% reproxalap ophthalmic solution, achieved the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber trial for the treatment of DED.

Together, these developments signal strong momentum within the DED treatment market, as the combination of a growing patient base, increasing awareness, and technological advancement positions the industry for substantial growth from 2025 onward.

However, the complications and safety concerns associated with dry eye disease treatment and stringent regulatory requirements for product approval, among others, are some of the key constraints that may limit the growth of the dry eye disease treatment market.

Dry Eye Disease Treatment Market Segment Analysis:

Dry Eye Disease Treatment Market by Product Type (Artificial Tears, Devices, Drugs, and Others), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the dry eye disease treatment market, the artificial tears category is estimated to account for the largest market share in 2024. The growth of this category is primarily driven by the increasing global prevalence of DED and the wide-ranging therapeutic benefits that artificial tears offer in managing the condition.

Artificial tears play a central role in DED management by supplementing or replacing the eye's natural tear film. They help maintain moisture on the ocular surface and provide immediate relief from common symptoms such as dryness, irritation, burning, and stinging sensations. These drops also reduce the gritty or sandy feeling often reported by patients, making everyday activities such as prolonged screen use, reading, or spending time in low-humidity environments more comfortable and manageable.

Beyond symptom relief, artificial tears form a protective barrier over the cornea and conjunctiva, helping to minimize mechanical friction caused by blinking and eyelid movement. This not only enhances comfort but also protects against further ocular surface damage, particularly in individuals with chronic or severe dry eye. Another key benefit is their ability to reduce ocular surface inflammation, a critical contributor to DED progression. Some artificial tear formulations include ingredients that help to calm irritation and support healing, thereby offering more than just symptomatic relief.

Furthermore, artificial tears aid in restoring and stabilizing the tear film's three essential layers, including lipid, aqueous, and mucin. By reinforcing this delicate structure, artificial tears enhance ocular surface lubrication and reduce tear evaporation, especially beneficial for patients suffering from evaporative forms of dry eye. Market growth is also being propelled by increasing R&D investments and product innovation. For example, in January 2022, NovaBay Pharmaceuticals launched Avenova(R) Lubricating Eye Drops, specially formulated to provide rapid and lasting relief for individuals suffering from dry eye symptoms. Innovations such as these highlight the segment's dynamic potential and ongoing evolution to meet the diverse needs of the patient population.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of dry eye disease treatment across the globe.

North America is expected to dominate the overall dry eye disease treatment market:

North America is projected to hold the largest share of the dry eye disease treatment market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising prevalence of dry eye disease and its associated risk factors, an increasing aging population, and ongoing product development and regulatory approvals by key market players. Collectively, these factors are positioning North America as the leading market in the global dry eye disease treatment market.

According to data from the National Institutes of Health (2025), nearly 16.4 million people in the United States were living with Dry Eye Disease (DED) in 2024. Further supporting this trend, DelveInsight Analysis (2025) reported that the total diagnosed prevalence of DED in the U.S. reached approximately 22.5 million cases in 2023. Similarly, data from Sjogren's Canada (2022) indicated that over 30% of the Canadian population was affected by dry eye disease, reflecting the widespread nature of the condition across North America. The growing number of DED cases, driven by aging demographics, increased screen time, and environmental stressors, is fueling demand for a broad range of treatment options, including artificial tears, medical devices, and advanced therapeutics.

Population growth is also playing a pivotal role in market expansion. According to the Population Reference Bureau (2024), the number of people aged 65 and older in the United States was projected to increase from 58 million in 2022 to 82 million by 2050, a 47% rise. This demographic shift will raise the share of older adults in the total population from 17% to 23%, significantly boosting demand for DED treatments, as aging is a major risk factor for the disease.

Market growth is further supported by a wave of recent product approvals and launches, reflecting continued innovation in the dry eye disease treatment space. In June 2023, Novaliq GmbH announced that the U.S. Food and Drug Administration (FDA) had approved VEVYE(TM) (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease. More recently, in February 2025, Alcon, a global leader in eye care, launched SYSTANE(R) PRO Preservative-Free (PF) in the United States. This over-the-counter eye drop features a unique triple-action, preservative-free formula and is currently the longest-lasting product in the SYSTANE range, offering extended relief from burning, dryness, and irritation.

Collectively, the rising disease burden, the expanding elderly population, and the continuous stream of innovative product introductions are expected to drive strong and sustained growth in the North American dry eye disease treatment market throughout the forecast period from 2025 to 2032.

Dry Eye Disease Treatment Market Key Players:

Some of the key market players operating in the dry eye disease treatment market include Alcon Inc., Johnson & Johnson Services, Inc., Sight Sciences, AbbVie Inc., Lumenis Be Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aldeyra Therapeutics, Inc., Viatris Inc., Tarsus Pharmaceuticals, Inc., MiBo Medical Group, Horus Pharma, OASIS Medical, Inc., VISUfarma, Santen Pharmaceutical Co., Ltd., Sentiss, Otsuka Pharmaceutical Co., Ltd., Novaliq GmbH, AFT Pharmaceuticals, NovaBay Pharmaceuticals, Inc., and others.

Recent Developmental Activities in the Dry Eye Disease Treatment Market:

• In May 2025, Grifols received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to begin a Phase 2 clinical trial of GRF312 Ophthalmic Solution, an immunoglobulin (IG) eye drop being developed as a potential new treatment for dry eye disease (DED).
• In May 2024, Nordic Pharma, Inc. launched LACRIFILL Canalicular Gel in the U.S., a novel therapy for dry eye disease. LACRIFILL is a cross-linked hyaluronic acid derivative, FDA-cleared to temporarily block tear drainage by occluding the canalicular system, thereby helping to retain moisture on the ocular surface.
• In January 2024, Alcon announced positive topline results from its two pivotal Phase 3 clinical trials, COMET-2 and COMET-3, which evaluated the efficacy and safety of AR-15512, an investigational treatment for the signs and symptoms of dry eye disease (DED).
• In September 2023, Bausch + Lomb Corporation announced the U.S. commercial launch of MIEBO (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first and only prescription eye drop approved specifically to target tear evaporation, addressing a key underlying cause of DED.

Key takeaways from the dry eye disease treatment market report study

• Market size analysis for current dry eye disease treatment market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the dry eye disease treatment market.
• Various opportunities available for the other competitors in the dry eye disease treatment market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current dry eye disease treatment market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the dry eye disease treatment market growth in the future?

Target audience who can benefit from this dry eye disease treatment market report study

• Dry eye disease treatment product providers
• Research organizations and consulting companies
• Dry eye disease treatment-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in dry eye disease treatment
• Various end-users who want to know more about the dry eye disease treatment market and the latest technological developments in the dry eye disease treatment market.

Frequently Asked Questions for the Dry Eye Disease Treatment Market:

1. What is dry eye disease?

• Dry eye disease treatment refers to the range of medical, therapeutic, and lifestyle interventions aimed at relieving symptoms, restoring the quality and quantity of tears, and improving the health of the ocular surface in patients suffering from Dry Eye Disease (DED). The goal is to reduce discomfort, prevent damage to the eye surface, and improve visual function.

2. What is the market for dry eye disease treatment?

• The dry eye disease treatment market was valued at USD 6,188.21 million in 2024, growing at a CAGR of 5.29% during the forecast period from 2025 to 2032 to reach USD 9,288.85 million by 2032.

3. What are the drivers for the dry eye disease treatment market?

• The growing need for dry eye disease treatment is primarily driven by the rising global prevalence of the condition. A key contributing factor is the expanding geriatric population, which is more susceptible to developing dry eye symptoms due to age-related changes in tear production and ocular health. Additionally, increased product development and frequent new launches by leading market players are further supporting market momentum. These trends are creating a favorable environment for sustained growth, positioning the dry eye disease treatment market for robust and steady expansion from 2025 to 2032.

4. Who are the key players operating in the dry eye disease treatment market?

• Some of the key market players operating in the dry eye disease treatment market include Alcon Inc., Johnson & Johnson Services, Inc., Sight Sciences, AbbVie Inc., Lumenis Be Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aldeyra Therapeutics, Inc., Viatris Inc., Tarsus Pharmaceuticals, Inc., MiBo Medical Group, Horus Pharma, OASIS Medical, Inc., VISUfarma, Santen Pharmaceutical Co., Ltd., Sentiss, Otsuka Pharmaceutical Co., Ltd., Novaliq GmbH, AFT Pharmaceuticals, NovaBay Pharmaceuticals, Inc., and others.

5. Which region has the highest share in the dry eye disease treatment market?

• North America is projected to hold the largest share of the dry eye disease treatment market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising prevalence of dry eye disease and its associated risk factors, an increasing aging population, and ongoing product development and regulatory approvals by key market players. Collectively, these factors are positioning North America as the leading market in the global dry eye disease treatment market.

Table of Contents

1. Dry Eye Disease Treatment Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Dry Eye Disease Treatment Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Dry Eye Disease Treatment Market Key Factors Analysis

• 5.1. Dry Eye Disease Treatment Market Drivers
  • 5.1.1. The growing prevalence of dry eye disease globally
  • 5.1.2. The growing elderly population, coupled with heightened disease awareness and detection
  • 5.1.3. Increasing product development and launch activities by key players
• 5.2. Dry Eye Disease Treatment Market Restraints and Challenges
  • 5.2.1. Complications and safety concerns associated with dry eye disease treatment
  • 5.2.2. Stringent regulatory requirements for product approval
• 5.3. Dry Eye Disease Treatment Market Opportunity
  • 5.3.1. Development of regenerative medicine and biologic therapies

6. Dry Eye Disease Treatment Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Dry Eye Disease Treatment Market Assessment

• 7.1. By Product Type
  • 7.1.1. Artificial Tears
  • 7.1.2. Devices
  • 7.1.3. Drugs
  • 7.1.4. Others
• 7.2. By Distribution Channel
  • 7.2.1. Hospital & Retail Pharmacies
  • 7.2.2. Online Pharmacies
• 7.3. By Geography
  • 7.3.1. North America
    • 7.3.1.1. United States Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.1.2. Canada Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.1.3. Mexico Dry Eye Disease Treatment Market Size in USD million (2022-2032)
  • 7.3.2. Europe
    • 7.3.2.1. France Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.2.2. Germany Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.2.3. United Kingdom Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.2.4. Italy Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.2.5. Spain Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.2.6. Rest of Europe Dry Eye Disease Treatment Market Size in USD million (2022-2032)
  • 7.3.3. Asia-Pacific
    • 7.3.3.1. China Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.3.2. Japan Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.3.3. India Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.3.4. Australia Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.3.5. South Korea Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.3.6. Rest of Asia-Pacific Dry Eye Disease Treatment Market Size in USD million (2022-2032)
  • 7.3.4. Rest of the World (RoW)
    • 7.3.4.1. Middle East Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.4.2. Africa Dry Eye Disease Treatment Market Size in USD million (2022-2032)
    • 7.3.4.3. South America Dry Eye Disease Treatment Market Size In USD Million (2022-2032)

8. Dry Eye Disease Treatment Market Company and Product Profiles

• 8.1. Alcon Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Johnson & Johnson Services, Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Sight Sciences
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. AbbVie Inc.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Lumenis Be Ltd.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Bausch Health Companies Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Sun Pharmaceutical Industries Ltd.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Aldeyra Therapeutics, Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Viatris Inc
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Tarsus Pharmaceuticals, Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. MiBo Medical Group
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Horus Pharma
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. OASIS Medical, Inc.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. VISUfarma
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Santen Pharmaceutical Co., Ltd.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Sentiss
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Otsuka Pharmaceutical Co., Ltd.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Novaliq GmbH
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. AFT Pharmaceuticals
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. NovaBay Pharmaceuticals, Inc.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us